Market Research Report
Global Frozen Shoulder Syndrome Market - 2021-2028
|Global Frozen Shoulder Syndrome Market - 2021-2028|
Published: July 28, 2021
Content info: 180 Pages
Delivery time: 2 business days
Frozen Shoulder Syndrome Market. Overview
The frozen shoulder syndrome market. The size was valued at US$ XX billion in 2020 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Frozen shoulder is also known as adhesive capsulitis. It is characterized by stiffness and pain in the shoulder joint. Signs and symptoms typically begin gradually, worsen over time, and resolve, usually within one to three years.
Frozen Shoulder Syndrome Market. Dynamics
The increased incidences of frozen shoulder will drive the market. And the high prevalence of diabetes and cardiovascular diseases may increase the risk of developing frozen shoulder.
The increased incidences of frozen shoulder will drive the market
The prevalence rate of frozen shoulder is estimated to be 2 to 5 percent of the general population. Frozen shoulder syndrome (FSS) usually affects patients aged 40-60 years. The incidence of FSS is not precisely known; however, it is estimated that 2% to 5% of the general population develops the disease over their lifetime. Men tend to be affected less frequently than women, and there is no preference for race. In general, bilateral shoulder involvement is rarely simultaneous and instead occurs sequentially.
Around 70% of individuals who suffer with a frozen shoulder are females. Among individuals 35-65 years old, with an occurrence rate of approximately 2-5% in the general population, In China and Japan, it's called the 50-year-old shoulder due to its prevalence at that age.
The high prevalence of diabetes and cardiovascular diseases may increase the risk of developing frozen shoulder
The musculoskeletal system can be affected in different ways by diabetes. The shoulder is one of the frequently affected sites of the body. Frozen shoulder (adhesive capsulitis) is one of the rheumatic conditions caused by diabetes. It is characterized by pain and severe limited active and passive range of motion of the glenohumeral joint, mainly external rotation. People with other health conditions, including heart disease, lung disease, chronic bronchitis, and diabetes, may have an increased risk of developing frozen shoulder. Cardiovascular disease, Parkinson's disease, and an overactive thyroid gland (hyperthyroidism) are also linked to this condition
The global diabetes prevalence in 2019 is estimated to be 9.3% (463 million people), rising to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The prevalence is higher in urban (10.8%) than rural (7.2%) areas and in high-income (10.4%) than low-income countries (4.0%).
Cardiovascular diseases (CVDs) are one of the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Moreover, over three-quarters of CVD deaths take place in low- and middle-income countries. Hence, with the rise in the incidence of these diseases, the frozen shoulder syndrome market will see a increase in the forecast period.
High treatment cost will hamper the market
Management of frozen shoulder is non-surgical, ranging from supervised neglect to joint distension, or surgical treatment in the form of manipulation under anesthesia (MUA), arthroscopic arthrolysis, or open capsular release. Non-surgical treatment is the first-line approach in most cases, followed by surgical intervention in those who fail to respond. There is limited high-quality evidence to support one treatment over another, be it surgical or non-surgical, with even less data on rates of surgery and cost-effectiveness. The cost of various non-surgical treatments may vary, with the surgical intervention being the highest.
Most of the treatments involve controlling shoulder pain and preserving as much range of motion in the shoulder as possible. OTC ( over-the-counter)pain relievers, such as aspirin and ibuprofen (Advil, Motrin IB, others), may help to reduce pain, inflammation associated with frozen shoulder. In some cases, a doctor may prescribe stronger pain-relieving and anti-inflammatory drugs.
A physical therapist can teach range-of-motion exercises to help recover as much mobility in the shoulder as possible. The commitment to doing these exercises is essential to optimize recovery of mobility
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown, which led to a huge impact on every sector, including the frozen shoulder syndrome market. In addition, the treatment was delayed due to the high demand for COVID-19 treatment in the hospitals.
Frozen Shoulder Syndrome Market. Segment Analysis
The physical Therapy type segment will dominate the market
The two major goals of frozen shoulder syndrome treatment are to increase motion and decrease pain. Much physical therapy and home exercises can be used as a first-line treatment for adhesive capsulitis. Physical therapy has shown to bring about pain relief and return of functional motion. When used in Medication with physical therapy, NSAIDs were proven to be more effective than using NSAIDs alone. Similarly, various studies on intra-articular corticosteroids used in Medication with physiotherapy resulted in better outcomes than intra-articular corticosteroids alone. Physical therapy for frozen shoulder involves using therapeutic modalities and procedures to decrease the pain and aggressive range of motion (ROM) exercises to help improve shoulder's mobility. PT should teach what to expect from treatment for frozen shoulder, and they should guide things that one can do to help ones condition.
In more than 90% of cases, frozen shoulder goes away with physical therapy and time. But, even when physical therapy is done consistently, it may still take up a year to gain back all lost shoulder function.
Hospitals will dominate the market
Hospitals have been seeing a growth in the market due to the presence of advanced medical equipmets. Structured physiotherapy for the treatment of frozen shoulder, is provided at low cost, is as effective as the other options available , and many people value the shorter waiting times. The availability of such treatments in hospitals as well as better facilities for physical therapies and staff to give better treatment will see a rise in the hospital segment of frozen shoulder syndrome market.
Frozen Shoulder Syndrome Market. Geographical Analysis
North America will dominate the frozen shoulder syndrome market
Due to an increase in R&D and technologically advanced products introduced in the market, this region will see a rise in its demand.
According to the American Academy of Orthopaedic Surgery, frozen shoulder incidences occur in 2% of the general population. Risk factors for frozen shoulder are both age and gender. Those between the ages of 40 and 60 are more likely to get frozen shoulder. It's also more common in women.
In Washington D.C [USA], on June 21st, a team of scientists developed a minimally invasive treatment that quickly reduces pain due to decreased errant blood flow to the shoulder and improves function in patients with adhesive capsulitis, also known as frozen shoulder.
Frozen Shoulder Syndrome Market. Competitive Landscape
The major players covered in the frozen shoulder syndrome market are GlaxoSmithKline plc, Contract Pharmacal Corp, Amneal Pharmaceuticals, Inc., Vintage Pharma, Dr. Reddy's Laboratories Ltd, Marksans Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Perrigo Company plc, Johnson & Johnson Services, Inc, .), Shanghai Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd.
Frozen Shoulder Syndrome Market. Key Companies to Watch
Overview: GlaxoSmithKline plc is a multinational British pharmaceutical company which has its headquarters in Brentford, England. Its is a science-led global healthcare company with a particular purpose: to help people do more, feel better, live longer. They have three global businesses that do research, develop and manufacture innovative pharmaceutical medicines, vaccines, and consumer healthcare products. They aim to bring, high-quality, differentiated and healthcare products that are needed to people, with their three global businesses, scientific and technical know-how, and talented people.
Product Portfolio: The company aims to bring high-quality, differentiated and needed healthcare products to many people, with their three global businesses, scientific, technical know-how, and talented people.
Key Development: On 6th August 2020, GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) had approved BLENREP (belantamab mafodotin-blmf). It is a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Key Development: Bayer adds menopause drugs to the pipeline with KaNDy acquisition. At the onset of the year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of menopause such as hot flashes and night sweats. A phase 3 trial is expected to have begun in 2021, and the company believes that the compound could generate peak sales of more than a billion euros globally.
The Frozen Shoulder Syndrome Market report would provide an access to an approx. 52 market data table, 43 figures and 200 pages.
Frozen Shoulder Syndrome Market- By Treatment
Frozen Shoulder Syndrome Market- By End-user
Frozen Shoulder Syndrome Market- By Region
LIST NOT EXHAUSTIVE